µoªí©óLancet Oncol 2018; 19: 323¡V36ªº¬ã¨s¡A¥Øªº¦b±´°QHER2¶§©ÊÂಾ©Ê¨ÅÀùªº¦Ñ¦~±wªÌ¡APertuzumab©Mtrastuzumab¦³ªvÀø·f°t©Î¤£·f°t¸`©ç¦¡¤fªA¤ÆÀøcyclophosphamideªºªºÀø®Ä¤ÀªR¡A¬O¤@¶µ¨Ó¦Û¦Ñ¦~¤HTask Force/¨ÅÀù²Õ´ªº¶}©ñ¼ÐÅÒ¡AÀH¾÷¡A²Ä¤G´ÁªºÁ{§É¸ÕÅç¡]EORTC
75111-10114¡^¡G
¸`©ç¦¡¤ÆÀø
¾¨ºÞÂಾ©Ê¨ÅÀùªº°ªµo¯f²v¤Î¨ä¦b¦Ñ¦~¤H¸s¤¤¦³¤@©w¬ÛÃö¦º¤`²v¡A¦ý§Ú̹ï¦Ñ¦~Àù¯g±wªÌªº³Ì¨ÎªvÀø»{ª¾¤WÁÙ¬O»·»·¤£°÷¡C¥H§Ü¦åºÞ·s¥Í»P§K¬Ì½Õ¸`§ï¨}¦¡ªº¸`©ç¦¡¤ÆÀø¡A¬Oªñ¤Q´X¦~¨Óªº¤@ºØ·sªºªvÀø¼Ò¦¡¡A³z¹L¬Û¹ï§CªºÃĪ«¾¯¶q¡B°ªÀW²v¥B«ùÄòÀ³¥Î²ÓM¬r±þ©ÊÃĪ«¡A¨ÏÃĪ«¯à°÷ªø®É¶¡ºû«ù¦b¬Û¹ï¸û§C¡B¦³®Äªº¦å¤¤ÃÄn¿@«×¡A¥H¹F¨ì©µªø¯e¯f±±¨î®É¶¡¡A¦P®É¤]¤j¤j°§CªvÀø°Æ§@¥Î¡C
¥»¬ã¨s¥Øªº¬Oµû¦ôHER2¶§©ÊÂಾ©Ê¨ÅÀù¦Ñ¦~±wªÌ¡A¨Ï¥Î§ÜHER2Âù¼Ð¹vªvÀø·f°t©Î¤£·f°t¸`©ç¦¡¤fªA¤ÆÀøcyclophosphamideªºÀø®Ä¡C
¬ã¨s¤èªk¦p¤U
¨Ó¦Û¼Ú¬w8Ó°ê®aªº30Ó¤¤¤ß¶i¦æ¤F¤@¶µ¦h¤¤¤ß¡A¶}©ñ¼ÐÅÒ¡AÀH¾÷©Êªº²Ä2´Á¸ÕÅç¡A¹ï©ó²Õ´¾ÇÃҹꪺHER2¶§©ÊÂಾ©Ê¨ÅÀù±wªÌ¡A¥ý«e¥¼±µ¨ü¤ÆÀø¤§Âಾ©Ê¯e¯f¡A¦~ÄÖ¦b70·³©Î¥H¤W¡A©Î¬O60·³©Î¥H¤W¦ý¨ã¦³¥Ñ¬ã¨s¤è®×½T»{ªº¥\¯à¨î¡A¨Ã¥B¹w´Á¹Ø©R¶W¹L12¶g©M®Ú¾ÚWHO 0-3ªºÅé¯àªí²{ª¬ºA¡C
³q¹L°ò©ó³Ì¤p¤Æªº¤èªk¡A¦b½uÀH¾÷¤Æ¨t²ÎÀH¾÷¤À°t¡]1¡G1¡^²Å¦X±ø¥óªº±wªÌ¡A¥H±µ¨ü¨C¤Ñ50mgªº¸`©ç¦¡¤fªA¤ÆÀøcyclophosphamide¥[§ÜHER2Âù¼Ð¹vªvÀø¡A©Î³æ¿Wªº§ÜHER2Âù¼Ð¹vªvÀø¡CÀR¯ßª`®gtrastuzumab¡At²ü¾¯¶q¬°8mg / kg¡AµM«á¨C3¶gª`®g6mg
/ kg¡CÀR¯ßª`®gPertuzumab¡At²ü¾¯¶q¬°840 mg¡AµM«á¨C3¶gª`®g420 mg¡C³q¹L¿E¯À¨üÅé¶§©Ê¡A¬J©¹HER2ªvÀø©M°ò½u¦Ñ¦~¿z¬d¹ï±wªÌ¶i¦æ¤À¼h¡C
®Ú¾Ú¹êÅé¸~½F¤ÏÀ³µû¦ô¼Ð·Ç¡]RECIST¡^²Ä1.1ª©¡A¸Ó¬ã¨s¥Dn²×ÂI¬O¬ã¨sªÌ©Òµû¦ôªº6Ó¤ëµL¯e¯f´c¤Æ¥Í¦s´Á¡C
¦Ü2013¦~7¤ë2¤é¦Ü2016¦~5¤ë10¤é´Á¶¡¡A80¦W±wªÌ¡]¨ä¤¤56¦W¡]¦û70¢H¡^¡AÄÝ©ó¦Ñ¦~¤H¿z¬dG8µû¤À¡]14¤À¥H¤U¡^¡Aªí¥Ü¨ã¦³¼ç¦bªº¯Ü®z¯S¼x¡C80¦W±wªÌ³QÀH¾÷¤À°t±µ¨ü§ÜHER2Âù¼Ð¹vªvÀø¡]39¦ì¡^©Î¥ÎHER2Âù¼Ð¹vªvÀø·f°t¸`©ç¦¡¤fªA¤ÆÀøcyclophosphamide ( 41¦ì¡^¡C
¬ã¨sµ²ªG
¦ôp©Ê¤§6Ӥ몺µL¯e¯f´c¤Æ¥Í¦s²v¡AHER2Âù¼Ð¹vªvÀøPertuzumab©Mtrastuzumab²Õ¬°46.2¢H¡A¥ÎHER2Âù¼Ð¹vªvÀø·f°t¸`©ç¦¡¤fªA¤ÆÀøcyclophosphamide«h¬°0¡P65
¡C

¤¤¦ì°lÂܮɶ¡¬°20¡P7Ó¤ë¡A¤¤¦ìµL¯e¯f´c¤Æ³¡¤ÀHER2¡AÂù¼Ð¹vªvÀørastuzumab©MPertuzumab¬°5¡P6Ó¤ë¡AHER2Âù¼Ð¹vªvÀø·f°t¸`©ç¦¡¤fªA¤ÆÀøcyclophosphamide«h¬°12¡P7Ó¤ë¡C
³Ì±`¨£ªº²Ä3-4µ¥¯Å°Æ§@¥Î¬O°ª¦åÀ£¡]Âù¼Ð¹vªvÀø²Õ¬°15¢H¡AHER2Âù¼Ð¹vªvÀø·f°t¸`©ç¦¡¤fªA¤ÆÀø¬O12¢H¡A¸¡Âm«h¤À§O¬°10¢H»P12¢H¡A©I§l§xÃø«h¤À§O¬°5¢H»P10¢H¡A¯h³Ò«h¤À§O¬°8¢H»P5¢H¡A¯kµh«h¤À§O¬°5¢H»P5¢H©M¦å®ê®ê¶ë¨Æ¥ó«h¤À§O¬°0¢H»P10¢H¡C
¨â²Õ¤¤³£¦³°¸º¸Æ[¹î¨ìÄY«ªº¤ßŦ¬r©Ê¡C
¹ï©ó¸Ó¬ã¨sªº¸ÑŪ¦p¤U:
¦bHER2¶§©ÊÂಾ©Ê¨ÅÀùªº¦Ñ¦~©MÅé®z±wªÌ¤¤¡A¹ï©óHER2Âù¼Ð¹vªvÀø·f°t¸`©ç¦¡¤fªA¤ÆÀøcyclophosphamide¡A»P³æ¥ÎÂù¼Ð¹vªvÀøtrastuzumab©MPertuzumabªvÀø¬Û¤ñ¡A¯e¯f±±¨î®É¶¡¥i¥H¼W¥[7Ó¤ë¡A¦Ó¥B¨ã¦³¥i±µ¨üªº¦w¥þ©Ê¡C
¹ï©óHER2¶§©ÊÂಾ©Ê¨ÅÀùªº¦Ñ¦~©MÅé®z±wªÌªºªvÀøµ¦²¤¡A¥i¥H¥ý¦æHER2Âù¼Ð¹vªvÀø·f°t¸`©ç¦¡¤fªA¤ÆÀøcyclophosphamide¡Cº¸«á¯e¯f´c¤Æ®ÉÔ¡A¥i¥H§ï¥Î²Ä¤T¥Ntrastuzumab
emtansine¡A¦p¦¹§@ªk¥i¯à·|©µ¿ð©Î¨ú¥N³oÃþ±Ú¸s¶i¦æµµ§ü¾J©ÎÖJ¤Æ¾¯¤Æ¾ÇªvÀøªº»Ýn¡C
¥t¥~¡A¸Ó¬ã¨sªºµ²ªG¤]Åã¥Ü¤F¡A³æ¿W¨Ï¥ÎHER2Âù¼Ð¹vªvÀøªýÂ_¡AÁöµM¥i¥HÁ×§K¤Æ¾ÇÀøªkªº°Æ§@¥Î¡AÅãµMµLªk¸ÉÀvÂಾ©ÊHER2¨ÅÀùªvÀø¤¤¹ê½è©Ê¬¡©Êªº³à¥¢¡C
¦ý¬O¦pªG¯à°÷¥[¤J§C±j«×¡B°ªÀW²v¤§¸`©ç¦¡¤fªA¤ÆÀø¡A¦pcyclophosphamide®É¡A§Ü¸~½F¬¡©Ê¦ü¥G·|¦]¦¹´£°ª¡A±o¨ìÃþ¦üCLEOPATRA¸ÕÅ窺µ²ªG¡A¯e¯f±±¨î®É¶¡¥i¥H¼W¥[7Ó¤ë¡A¦Ó¥B¨ã¦³¬Û¹ï°ª«×¥i¥H±µ¨üªº¦w¥þ©Ê¡A·¥¬°HER2¶§©ÊÂಾ©Ê¨ÅÀùªº¦Ñ¦~©MÅé®z±wªÌ©Ò±À±R¡C

Á`¤§¡A¦bHER2¶§©ÊÂಾ©Ê¨ÅÀùªº¦Ñ¦~©MÅé®z±wªÌ¤¤¡AHER2Âù¼Ð¹vªvÀøªýÂ_¥[¤W¸`©ç¦¡¤fªA¤ÆÀø¡A¦ü¥G¤ñ³æ¿WHER2Âù«ªýÂ_´£¨Ñ¤F§ó¦nªº¹w«á¡A¨Ã¥B¨ã¦³¥i±µ¨üªº¦w¥þ©Ê¡Cº¸«á¯e¯f´c¤Æ®ÉÔ¡A¥i¥H§ï¥Î²Ä¤T¥Ntrastuzumab emtansine¡A¦p¦¹§@ªk¥i¯à·|©µ¿ð©Î¨ú¥N³oÃþ±Ú¸s¦]¯f±¡´c¤Æ¡BªvÀøªÅ¶¡¯U¹i¦Ó³Q¢¶i¦æ¤Æ¾ÇªvÀøªº»Ýn¡C
³¯Â@¶hÂå®v¥Ø«e¾á¥ôÀù¯g¤¤Âå»P¦èÂåÁ{§ÉªvÀøÂå®v¡AµÛ¦³¡¨À»°hÀù¯h¾Î
Âå®v¸Ó§i¶D§AªºÀù«á¾i¥Í³N¡¨(±d°·¥Xª©)¡A±M¾¤¤¦èÂåµ²¦XÀù¯gªvÀø»PÀù¤ÍÃöÃh¤§¤½¯q¬¡°Ê¡A¦P®É¼ö¤ßP¤O©ó¥¿½TÀù¯g·ÓÅ@¸ê°T¤§±À¼s»P¶Ç»¼¡A¨ä©Ò³Ð«Ø¤§¥x¤¤¥«¥þ¤è¦ìÀù¯gÃöÃh¨ó·|http://www.cancerinfotw.org ¡A¤D¬O±M·~·ÓÅ@¤Hû¡BªÀ·|½å¹F°^Äm©Ò¾Ç¡A©Ò«ØºcªºÀù¯g¶EÀø»P·ÓÅ@¸ê°T¥»O¡C
¦¹³B¤å³¹¤D¬OÂåÀø·ÓÅ@¸ê°Tªº¾ã²z¡A½Ð¤Å¤Þ¾Ú¤å³¹¤º®e¦Û¦æ±Ä¨úÂåÀø¨M©w¡F¦p¦³Á{§ÉªvÀø¤§»Ý¨D¡A«ØÄ³ÁÙ¬OÀ³¸Ó´M¨D±M·~ÂåÀø¤Hûªº¨ó§U¡C¦p¦³¥ô¦óÂÕ»~©Î«ØÄ³¡AÀµ½Ð¤£§[«ü±Ð¡C
·Qn¾\Äý§@ªÌ¼¶¼gªº§ó¦h¬ÛÃöÀù¯g¸ê°T¡AÅwªï«e©¹³¯Â@¶hÂå®v©xºô¡¨¸Ü²áѼֳ¡¡¨
http://cancerfree.medicalmap.tw/ ¡C
·QnÁA¸Ñ§@ªÌªº¸ê°T¤]½Ð¦Ühttp://cancerfree.medicalmap.tw/ ÂI¾\¡¨³¯Â@¶hÂå®v²¤¶¡¨
|